Novartis

Lore & Background

The merger was considered the largest corporate merger in history at that time. The name Novartis was based on the Latin terms novae artes (new skills). After the merger, other Ciba-Geigy and Sandoz businesses were sold or spun off, such as Ciba Specialty Chemicals. The Sandoz brand disappeared for three years but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary named Sandoz. In the mid-1990s, state and federal agencies identified an increased incidence of childhood cancers in Toms River, New Jersey, linked to contamination from the Toms River Chemical Plant operated by Ciba-Geigy.

Reader's Guide

Novartis represents a significant consolidation in the pharmaceutical industry, merging two major Swiss chemical and drug companies into a global powerhouse. The company's product portfolio includes blockbuster drugs like Gleevec for cancer and Diovan for hypertension, as well as widely used generics through its Sandoz subsidiary. Novartis has also been involved in controversies, notably the Toms River cancer cluster linked to a former Ciba-Geigy plant, which became the subject of a Pulitzer Prize-winning book. Novartis remains a full member of major pharmaceutical industry associations and is the third most valuable pharmaceutical company in Europe.

Did You Know?

• The name Novartis is based on the Latin terms novae artes, meaning 'new skills'.

A Swiss Merger That Redefined Big Pharma

Novartis was born in March 1996 when two Swiss pharmaceutical giants, Ciba-Geigy and Sandoz Laboratories, combined their pharmaceutical and agrochemical operations into a single independent entity. At the time of the deal, the union was widely regarded as the largest corporate merger in history. The new company drew its name from the Latin phrase novae artes, meaning new skills, a nod to the creative fusion of two legacy firms. Ciba-Geigy itself was the product of a 1970 merger between CIBA, which traced its roots to Alexander Clavel's 1859 silk-dyeing factory in Basel, and J. R. Geigy, founded in 1857 by Johann Rudolf Geigy-Merian and Johann Muller-Pack. Sandoz, meanwhile, had been established in 1886 by Alfred Kern and Edouard Sandoz, initially producing dyes before pivoting toward pharmaceuticals under Arthur Stoll in 1917. The combined entity began full operations on 20 December 1996, and by 2024 it had grown into the eighth-largest pharmaceutical company globally by revenue.

A Portfolio Spanning Oncology, Psychiatry, and Beyond

Novartis's commercial portfolio reflects the breadth of its two predecessor companies. Among its most recognizable products are imatinib mesylate, marketed as Gleevec or Glivec, a landmark targeted therapy for certain cancers; clozapine, sold as Clozaril, an antipsychotic originally developed by Sandoz; and cyclosporine, known as Neoral or Sandimmune, a cornerstone of organ-transplant medicine. The company also produces valsartan (Diovan) for hypertension, carbamazepine (Tegretol) for epilepsy, letrozole (Femara) for breast cancer, methylphenidate (Ritalin) for ADHD, terbinafine (Lamisil) for fungal infections, and deferasirox (Exjade) for iron overload. In 2015, Novartis sold its diclofenac franchise, Voltaren, to GlaxoSmithKline, and methylphenidate production shifted to Sandoz in 2023. The Sandoz brand, which had vanished for three years after the merger, was revived in 2003 when Novartis consolidated all of its generic-drug operations under that name, creating a dedicated subsidiary for lower-cost medicines.

Carving Out a Focused Pharma Giant

In the years following the 1996 merger, Novartis undertook a series of divestitures and spin-offs to sharpen its identity as a pure-play pharmaceutical company. The most consequential move came in 2000, when the company's agrochemical and genetically modified crops division was spun out as Syngenta, a joint venture with AstraZeneca, which simultaneously divested its own agrochemical business. Ciba Specialty Chemicals was similarly separated as an independent entity. These restructurings stripped away non-core operations and allowed Novartis to concentrate capital and management attention on drug discovery and commercialization. The company also pursued a string of acquisitions designed to reinforce its core therapeutic areas. By the 2020s, Novartis had cemented its position as the third most valuable pharmaceutical company in Europe, trailing only Novo Nordisk and Roche. It maintains full membership in major industry bodies including EFPIA, BIO, IFPMA, and PhRMA, underscoring its role as a central player in global pharmaceutical policy and research.

The Toms River Shadow

Novartis's corporate history carries a significant environmental controversy rooted in its predecessor Ciba-Geigy. Between 1970 and 1995, state and federal health and environmental agencies documented a troubling rise in childhood cancers in Toms River, New Jersey. Multiple investigations pointed to contamination emanating from the Toms River Chemical Plant, which Ciba-Geigy had operated since 1952, as well as from the nearby Reich Farm and Union Carbide site. The area was designated a U.S. EPA Superfund site in 1983 after an underground plume of toxic chemicals was discovered, and a leaking discharge pipe was shut down the following year after a sinkhole exposed the problem. The plant ceased operations in 1996. A subsequent 1996-to-2000 study found that while cancer cases remained above expectations, rates had dropped sharply and the difference was no longer statistically significant relative to statewide norms. The Toms River water system now undergoes the most rigorous testing in New Jersey. Dan Fagin's 2014 Pulitzer Prize-winning book, Toms River: A Story of Science and Salvation, brought national attention to the decades-long industrial pollution saga.

Gallery